[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368407-105":59,"doc-detail-368407-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","second-primary-cancers-among-males-with-a-first-primary-prostate-cancer-a-population-based-study-in-northern-portugal","Second primary cancers among males with a first primary prostate cancer - a population-based study in Northern Portugal","","Increased survival after prostate cancer elevates the risk of a second primary cancer (SPC). This study describes SPC occurrence in a Northern Portugal population-based cohort of 13,222 men diagnosed with a first primary prostate cancer between 2000 and 2009, followed through 31 December 2021. Frequencies, incidence rates, standardized incidence ratios versus the male general population, and cumulative incidence of metachronous SPCs were estimated, showing 14.8% developing an SPC.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/second-primary-cancers-among-males-with-a-first-primary-prostate-cancer-a-population-based-study-in-northern-portugal/368407/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/second-primary-cancers-among-males-with-a-first-primary-prostate-cancer-a-population-based-study-in-northern-portugal/368407.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main objective of the study?","Question",{"text":113,"@type":114},"To quantify the incidence rates and risk of second primary cancers (SPCs) among men with a first primary prostate cancer in Northern Portugal, and to compare observed SPC incidence with expected incidence in a matched population.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the study cohort defined and how long were patients followed?",{"text":118,"@type":114},"The cohort included 13,222 patients diagnosed with a prostate first primary cancer between 2000 and 2009. Patients were followed until 31 December 2021, with up to 22 years of follow-up.",{"name":120,"@type":111,"acceptedAnswer":121},"What outcomes were reported about second primary cancers?",{"text":122,"@type":114},"The study reported absolute and relative SPC frequencies, incidence rates and standardized incidence ratios compared to the male general population, and the 20-year cumulative incidence of metachronous SPCs.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368407,1790239719,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Clinical and Experimental Medicine (2025) 25:122 [https://doi.org/10.1007/s10238-025-01654-7](https://doi.org/10.1007/s10238-025-01654-7)  \nSecond primary cancers among males with a first primary prostate cancer: a population‑based study in Northern Portugal  \nJosé Taveira‑Barbosa1,2 · Samantha Morais3,4 · Teresa Garcia1,2,5 · Maria José Bento2,5,6 · Nuno Lunet1,3,4  \nReceived: 24 February 2025 / Accepted: 26 March 2025 / Published online: 21 April 2025 © The Author(s) 2025  \nAbstract  \nIncreased survival and life expectancy among patients with prostate cancer results in an increased risk of developing a second primary cancer (SPC) . We aimed to describe the occurrence of SPCs in a population-based cohort with a prostate first primary cancer (FPC), in Northern Portugal. A cohort of 13,222 patients with a prostate FPC from the North Region Cancer Registry of Portugal, diagnosed between 2000 and 2009, was followed until 31 December 2021, for synchronous (within six months ofFPC diagnosis) and metachronous SPCs (all others) . We describe absolute and relative frequencies of SPCs, incidence rates and standardized incidence ratios of SPCs (compared to the male general population), and cumulative incidence of metachronous SPCs. A total of 1953 (14.8%) patients with a prostate FPC developed an SPC, mostly of the colon, lung and bladder; synchronous SPCs occurred mainly in the bladder. Compared to the general male population, patients with a prostate FPC had a globally lower incidence of all cancers, and lung and oesophagus cancers, but a higher incidence of bladder and pancreas cancers. Overall, the incidence of synchronous SPCs was also significantly higher, likely reflecting the incidental diagnosis of SPCs. The 20-year cumulative incidence of metachronous SPCs was 15.4% . Patients with a prostate FPC had a lower overall incidence of SPCs than the general male population, despite a higher incidence in the first six-months after the SPC diagnosis. After that period, one out of seven may be expected to develop an SPC within two decades. Continued cancer surveillance among survivors is needed.  \nKeywords Second primary neoplasm · Prostatic neoplasm · Population register · Epidemiology  \n* Nuno Lunet[nlunet@med.up.pt](nlunet@med.up.pt)  \n1 Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina, Universidadedo Porto, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal  \n2 Serviço de Epidemiologia, Instituto Português de Oncologia do Porto FG, EPE, Porto, Portugal  \n3 EPIUnit, Instituto de Saúde Pública da Universidadedo Porto, Porto, Portugal  \n4 Laboratório Para a Investigação Integrativa e Translacionalem Saúde Populacional (ITR), Porto, Portugal  \n5 Grupo de Investigação em Epidemiologia, Resultados, Economia e Gestão em Oncologia-Centro de Investigação (CI-IPOP) and Porto Comprehensive Cancer Center (Porto.CCC) and RISE@CI-IPOP (Rede de Investigação em Saúde), Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto, Portugal  \n6 Departamento Estudos de Populações, Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, Porto, Portugal  \nIntroduction  \nWorldwide, prostate cancer (PCa) represents the second most common tumor diagnosed and ranks fifth in mortality among males in 2022 [1] . PCa is the most prevalent cancer with more than five million men alive five-years after diagnosis [1] . Furthermore, the worldwide incidence of PCa is expected to double by 2040 [2] . In Portugal, PCa ranks first in incidence and third in mortality among males, with an estimated 29-thousand males living with PCa five-years after diagnosis [1] .  \nSurvival from PCa has been increasing, with current estimates for 10-and 15-year relative survival at 98% and 91%, respectively [3], resulting from continuous improvements in diagnosis and treatments [4, 5] . Increased survival and life expectancy among patients with PCa results in increased risk for several adverse health events such","cbCaikND0c4rJ3c0","https://ap.wps.com/l/cbCaikND0c4rJ3c0","pdf",988041,11,"English","# Abstract\n# Introduction\n# Methods\n## Study setting (study population and data source)\n## Tumour classification and definition of second primary cancers","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To quantify the incidence rates and risk of second primary cancers (SPCs) among men with a first primary prostate cancer in Northern Portugal, and to compare observed SPC incidence with expected incidence in a matched population.\"},{\"question\":\"How was the study cohort defined and how long were patients followed?\",\"answer\":\"The cohort included 13,222 patients diagnosed with a prostate first primary cancer between 2000 and 2009. Patients were followed until 31 December 2021, with up to 22 years of follow-up.\"},{\"question\":\"What outcomes were reported about second primary cancers?\",\"answer\":\"The study reported absolute and relative SPC frequencies, incidence rates and standardized incidence ratios compared to the male general population, and the 20-year cumulative incidence of metachronous SPCs.\"}]","Second primary cancers among males with a first primary prostate cancer - a population-based study in Northern Portugal | PDF",1790176787,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aca9e9f387b5e8d5f69f16996ea3abf7.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ece3ac0d4cfb92fc150c5081fbcbe11e.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea34ec2c6d4b81e1096458a8823ea7e1.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c17fde52005cab1031c8edde11dc4b9f.webp",980,1301]